The SYPRO Orange thermal shift assay was employed to screen VinSpinIn and VinSpinIC against a panel of methyl binding domains (MBDs), which included four of the five Spin family members (Table 1). VinSpinIn induced a large shift in thermal stability of Spin1, Spin2B, Spin3, Spin4. No other significant shift in thermal stability was observed for VinSpinIn or the inactive VinSpinIC.

Table 1: Screening on a panel of MBDs.^a protein = 0.05 to 0.2 mg/ml, compound = 200 µM; ^b protein = 2 µM, compound = 20 µM; ^c Intrinsic tryptophan fluorescence used

A fluorescence polarization displacement assays was employed to screen the compounds against L3MBTL1 and L3MBTL3 (MBT methyl lysine readers), which gave respective K_disp.s of 27 and 8 µM for VinSpinIn, and 28 and 14 µM for the inactive VinSpinIC. Therefore, VinSpinIn is approximately 267 times less potent towards L3MBTL1 than Spin1.

Selectivity screening was also performed against a panel of methyl transferases domains (MTDs) including protein, DNA and RNA methyltransferases using a Scintillation Proximity Assay (SPA) (Figure 1).

Figure 1: (Top) Methyltransferase activity in presence of VinSpinIn at 10 & 50 µM
(Bottom) Methyltransferase activity in presence of VinSpinIC at 10 and 50 µM.

For selected targets IC₅₀s were determined (Table 2). The lowest IC₅₀ of VinSpinIn (PRMT4) was approximately 300 times greater than the AlphaScreen IC₅₀ on Spin1.

Table 2: IC₅₀s of selected methyltransferases.^a Not determined

Materials and Methods

Effects of VinSpinIn  and VinSpinIC on methyltransferase activity of G9a, GLP, SUV39H1, SUV39H2, SETDB1, SETD8, SUV420H1, SUV420H2, SETD7, MLL1 trimeric complex, MLL3 pentameric complex, EZH2 trimeric complex, PRMT1, PRMT3, PRMT4, PRMT5-MEP50 complex, PRMT6, PRMT7, PRMT8, PRMT9, PRDM9, SETD2, SMYD2, SMYD3, and DNMT1 was assessed by monitoring the incorporation of tritium-labeled methyl group to lysine or arginine residues of peptide substrates using Scintillation Proximity Assay (SPA) as previously described¹⁴.  Assays were performed in a 10 µl reaction mixture containing ³H-SAM (Cat.# NET155V250UC; Perkin Elmer; www.perkinelmer.com) at substrate concentrations close to K_m values for each enzyme.  Two concentrations (10µM and 50 µM) of VinSpinIn or  VinSpinIC  were used in all selectivity assays.  To stop the enzymatic reactions, 10 µl of 7.5 M guanidine hydrochloride was added, followed by 180 µl of buffer (20 mM Tris, pH 8.0), mixed and then transferred to a FlashPlate (Cat.# SMP103; Perkin Elmer; www.perkinelmer.com). After mixing, the reaction mixtures in Flash plates were incubated for 2 hours and the CPM were measured using Topcount plate reader (Perkin Elmer, www.perkinelmer.com). The CPM counts in the absence of compound for each data set were defined as 100% activity. In the absence of the enzyme, the CPM counts in each data set were defined as background (0%).

For DOT1L, NSD1, NSD2, NSD3, ASH1L, DNMT3A/3L, and DNMT3B/3L, a filter-based assay was used. In this assay, 10 µl of reaction mixtures were incubated at 23 ^oC for 1 hour, 50 µl of 10% trichloroacetic acid (TCA) was added, mixed and transferred to filter-plates (Millipore; cat.# MSFBN6B10; www.millipore.com). Plates were centrifuged at 2000 rpm (Allegra X-15R - Beckman Coulter, Inc.) for 2 min followed by 2 additional 10% TCA wash and one ethanol wash followed by centrifugation. Plates were dried and 30 µl MicroO (MicroScint-O; Cat.# 6013611, Perkin Elmer; www.perkinelmer.com) was added to each well, centrifuged and removed. 50 µl of MicroO was added again and CPM was measured using Topcount plate reader.

IC₅₀ Determinations:
IC₅₀ values were determined for inhibition of methyltransferase activity of the following enzymes:

• PRMT4 (20 nM PRMT4, 1 µM of biotinlated-H3 1-25, 2 µM of ³H-SAM)
• SETD2 (150 nM SETD2, 0.5 µM of biotinylated-H3 21-44, 5 µM of ³H-SAM)
• PRMT7 (25 nM PRMT7, 0.3 µM of biotinylated-H2B(23-37), 1 µM of ³H-SAM)
• SUV39H1 (20 nM SUV30H1, 0.2 µM of biotinlated-H3 1-25, 5 µM of ³H-SAM)
• PRMT6 (20 nM PRMT6, 1 µM of biotinlated-H4 1-24, 2 µM of ³H-SAM)
• PRC2 (20 nM PRC2, 1 µM of biotinlated-H3 21-44, 2 µM of ³H-SAM)
• SMYD2 (30 nM SMYD2, 3 µM of biotinlated-P⁵³peptide, 0.3 µM of ³H-SAM)
• PRDM9 (5 nM PRDM9, 4 µM of biotinlated-H3 1-25, 71 µM of SAM)
• PRMT1 (15 nM PRMT1, 0.13 µM of biotinlated-H4 1-24, 5 µM of ³H-SAM)
• PRMT8 (20 nM PRMT8, 1 µM of biotinlated-H4 1-24, 2 µM of ³H-SAM)
• DNMT3A/3L (20 nM DNMT3A/3L, 0.5 µM of poly DI-DC, 1 µM of ³H-SAM)
• DNMT3B/3L (50 nM DNMT3B/3L, 0.5 µM of poly DI-DC, 1 µM of ³H-SAM)
• G9a (5 nM G9A, 0.8 µM of biotinlated-H3 1-25, 10 µM of SAM)
• GLP (5 nM Glp, 0.8 µM of biotinlated-H3 1-25, 10 µM of SAM).

To stop the enzymatic reactions, 7.5 M Guanidine hydrochloride was added, followed by 180 µL of buffer (20 mM Tris, pH 8.0), mixed and then transferred to a FlashPlate (Cat.# SMP103; Perkin Elmer; www.perkinelmer.com). After mixing, the reaction mixtures in Flash plate were incubated for 2 hour and the CPM counts were measured using Topcount plate reader (Perkin Elmer, www.perkinelmer.com). The CPM counts in the absence of compound for each data set were defined as 100% activity. In the absence of the enzyme, the CPM counts in each data set were defined as background (0%). The IC₅₀ values were calculated using GraphPad Prism 7 software.

In a NanoBRET cellular target engagement assay VinSpinIn displayed dose dependant inhibition of the Spin1-H3 interaction, with an IC₅₀ of 270 nM. The inactive VinSpinIC showed no inhibition (Figure 1).

Figure 1: NanoBRET cellular target engagement assay performed in U2OS cells. Full length SPIN1 with N-terminal NanoLuc; Histone 3.3 with C-terminal Halotag; 24h incubation with VinSpinIn and VinSpinIC

Materials and Methods

U20S cell (2.8 x 10⁵) were plated in each well of a 6-well plate after 6h cells were co-transfected with C-terminal HaloTag-Histone 3.3 (NM_002107) and an N-terminal NanoLuciferase fusion of full length SPIN1 at a 1:500 (NanoLuc® to HaloTag®) ratio respectively with FuGENE HD transfection regent¹⁵.

Sixteen hours post-transfection, cells were collected, washed with PBS, and exchanged into media containing phenol red-free DMEM and 4% FBS in the absence (control sample) or the presence (experimental sample) of 100 nM NanoBRET 618 fluorescent ligand (Promega). Cells were then re-plated in a 384-well assay white plate (Greiner #3570) at 2.7x10³ cells per well.  VinSpinIn and VinSpinIC were then added directly to media at final concentrations 0-30μM or an equivalent amount of DMSO as a vehicle control, and the plates were incubated for 24 h at 37^oC in the presence of 5% CO₂.

NanoBRET Nano-Glo substrate (Promega) was added to both control and experimental samples at a final concentration of 10 µM.  Readings were performed within 10 minutes using a ClarioSTAR (BMG labtech) equipped with 460 nm and 610 nm filters.  A corrected BRET ratio was calculated and is defined as the ratio of the emission at 610 nm/460 nm for experimental samples minus the emission at 610 nm/460 nm for control samples (without NanoBRET fluorescent ligand). BRET ratios are expressed as milliBRET units (mBU), where 1 mBU corresponds to the corrected BRET ratio multiplied by 1000.

1. https://www.proteinatlas.org/search/Spindlin.
2. Su, X. et al. Molecular basis underlying histone H3 lysine-arginine methylation pattern readout by Spin/Ssty repeats of Spindlin1. Genes Dev 28, 622-636, doi: 10.1101/gad.233239.113 (2014).
3. Yang, N. et al. Distinct mode of methylated lysine-4 of histone H3 recognition by tandem tudor-like domains of Spindlin1. Proc Natl Acad Sci U S A 109, 17954-17959, doi: 10.1073/pnas.1208517109 (2012).
4. Zhao, Q. et al. Structure of human spindlin1. Tandem tudor-like domains for cell cycle regulation. J Biol Chem 282, 647-656, doi: 10.1074/jbc.M604029200 (2007).
5. Wang, W. et al. Nucleolar protein Spindlin1 recognizes H3K4 methylation and stimulates the expression of rRNA genes. EMBO Rep 12, 1160-1166, doi: 10.1038/embor.2011.184 (2011).
6. Shanle, E. K. et al. Histone peptide microarray screen of chromo and Tudor domains defines new histone lysine methylation interactions. Epigenetics Chromatin 10, 12, doi: 10.1186/s13072-017-0117-5 (2017).
7. Wang, J. X. et al. SPINDLIN1 Promotes Cancer Cell Proliferation through Activation of WNT/TCF-4 Signaling. Mol Cancer Res 10, 326-335, doi: 10.1158/1541-7786.Mcr-11-0440 (2012).
8. Franz, H. et al. The histone code reader SPIN1 controls RET signaling in liposarcoma. Oncotarget 6, 4773-4789, doi: 10.18632/oncotarget.3000 (2015).
9. Chen, X. et al. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. J Pathol 239, 459-472, doi: 10.1002/path.4743 (2016).
10. Li, Y., Ma, X., Wang, Y. & Li, G. miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway. Biomed Pharmacother 93, 435-443, doi: 10.1016/j.biopha.2017.06.058 (2017).
11. Fang, Z. et al. SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein 18)-MDM2-p53 pathway in human cancer. Elife 7, doi: 10.7554/eLife.31275 (2018).
12. Chen, X. et al. Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway. Am J Transl Res 9, 90-102 doi: 10.1042/BSR20170682 (2017).
13. Drago-Ferrante, R. et al. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget 8, 28939-28958, doi: 10.18632/oncotarget.15960 (2017).
14. Barsyte-Lovejoy, D. et al. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells, PNAS 111, 12853-12858. doi: 10.1073/pnas.1407358111 (2014).
15. Machleidt, T. et al. NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. ACS Chem Biol 10, 1797-1804, doi: 10.1021/acschembio.5b00143 (2015).

The co-crystal structure of Spin1 with VinSpinIn confirms that VinSpinIn binds to both domain 1 and 2 of Spin1, and therefore is referred to as a bidentate inhibitor (Figure 1).

Figure 1: Co-crystal structure of Spin1 (domain 1 = purple; domain 2 = green; domain 3 = yellow) with VinSpinIn (Cyan).

A KINOMEscan of DDR-TRK-1 at 1μM revealed very few off-targets:

An activity assay at RBC (10μM ATP) revealed the following within the DDR/TRK family:

Dose-response curves for the probe (and where collected, the negative control) are shown below:

In a NanoBRET^TM cellular target engagement assay DDR1-TRK-1 displayed dose dependant inhibition as follows:

NanoBRET assay
Dose-response experiments were conducted in 96 well format using HEK293T cells expressing NanoLuc fused to the C-terminus of full-length protein kinases for DDR2, TRKA and TRKB or isoform 2 for DDR1, using Promega tracer  as indicated below.

1. Carafoli F., et al., Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure 2009, 17 1573–1581.
2. Noordeen N.A., et al., A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1. J Biol Chem 2006, 281, 22744–22751.
3. Vogel W.F., Abdulhussein R., Ford C.E. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signalling2006, 18, 1108–1116.
4. Valiathan R.R., et al., Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev2012, 31, 295–321.
5. Franco C., et al., Discoidin domain receptor 1 (DDR1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res2008, 102, 1202–1211.
6. Yang S.H., et al., Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep2010, 24, 311–319.
7. Shimada K., et al., Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer. Cancer Sci 2008, 99, 39–45.
8. Hammerman P.S., et al., Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov2011, 1, 78–89.
9. Zhang K., et al., The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol2013, 15, 677–687.
10. Valencia K., et al., Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res2012, 18, 969–980.
11. Guerrot D., et al., Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol2011, 179, 83–91.
12. Lange, A.; Lo, H.-W., Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers (Basel) 2018, 10 (4), 105.

Structures of DDR1 complexes. A. Overall view of DDR1. Structural features are labelled for clarity. N-lobe is coloured orange,  A loop is marked in yellow and C-lobe is coloured wheat. B. D2099 compound electron density (PDB 5FDP). C. D2164 compound electron density (PDB 5FDX). D. Molecular docking of DDR-TRK-1 compound.

Inhibition of DDR1, DDR2, TRKA, TRKB and TRKC kinase activity was measured using radiometric assay (Reaction Biology Corporation). Compounds were tested in 10-dose IC50 singlicate mode with a 3-fold serial dilution starting at 1 or 10 μM at [ATP] = 10 µM.

Kinome-wide profiling was performed at DiscoverX using the KINOMEscan assay.

Probe		Negative control
SKI-73		SKI-73N

• SMILES:
• SKI-73: CC1=C(C(C(C(C)(CC(N[C@H](C(NCCC2=CC=C(OC)C=C2)=O)CC[C@H](CNCC3=CC=CC=C3)C[C@@H]4[C@@H](O)[C@@H](O)[C@@H](O4)N5C=NC6=C5N=CN=C6N)=O)C)=C(C1=O)C)=O)C
• SKI-73N: CC1=C(C(C(C(C)(CC(N[C@H](C(NCCC2=CC=C(OC)C=C2)=O)CC[C@H](NCC3=CC=CC=C3)C[C@@H]4[C@@H](O)[C@@H](O)[C@@H](O4)N5C=NC6=C5N=CN=C6N)=O)C)=C(C1=O)C)=O)C
• InChI:
• SKI-73: InChI=1S/C46H58N8O8/c1-26-27(2)39(57)36(28(3)38(26)56)46(4,5)21-35(55)53-33(44(60)49-19-18-29-12-15-32(61-6)16-13-29)17-14-31(23-48-22-30-10-8-7-9-11-30)20-34-40(58)41(59)45(62-34)54-25-52-37-42(47)50-24-51-43(37)54/h7-13,15-16,24-25,31,33-34,40-41,45,48,58-59H,14,17-23H2,1-6H3,(H,49,60)(H,53,55)(H2,47,50,51)/t31-,33-,34+,40+,41+,45+/m0/s1
• SKI-73N: InChI=1S/C45H56N8O8/c1-25-26(2)38(56)35(27(3)37(25)55)45(4,5)21-34(54)52-32(43(59)47-19-18-28-12-15-31(60-6)16-13-28)17-14-30(48-22-29-10-8-7-9-11-29)20-33-39(57)40(58)44(61-33)53-24-51-36-41(46)49-23-50-42(36)53/h7-13,15-16,23-24,30,32-33,39-40,44,48,57-58H,14,17-22H2,1-6H3,(H,47,59)(H,52,54)(H2,46,49,50)/t30-,32-,33+,39+,40+,44+/m0/s1
• InChIKey:
• SKI-73: HZHUKQLWLNDVDZ-IBDVCRJISA-N
• SKI-73N: NEMZJATUXVLJBZ-AEPDLXTASA-N

Main features

• Overall structure of (S)-SKI-72 with PRMT4 showing dimeric crystal structure
• PRMT4 with sinefungin and H3R17me
• (S)-SKI-72 occupies both the SAM and peptide pockets
• (S)-SKI-72 binding interactions

• Böttcher, J., Dilworth, D., Reiser, U., Neumüller, R., Schleicher, M., & Petronczki, M. et al. (2019). Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Nature Chemical Biology. doi: 10.1038/s41589-019-0310-x

Main features

• Predicted binding mode with H3K36me3
• Overlay with BI-9321 structure
• Zoomed BI-9321 structure showing hydrogen bonds

Main features

• Active form of mPRDM9 showing H3 peptide stabilized by C-terminus of SET domain (orange).
• Overlay with inactive form of hPRDM9 which does not contain SAM or H3 peptide. Note the displacement of the helix (blue) which is stabilized in the active form (orange).
• Binding of MRK-740 destabilizes the helix in similar manner to that of the apo-form (blue).
• Overview of MRK-740 bound to mPRDM9 with SAM.
• Detailed view of MRK-740 binding.